pibrentasvir Inhibitors
1 drugsAbout pibrentasvir
Pibrentasvir is a drug target for Hepatitis C virus (HCV) infection. It functions by inhibiting viral replication, a crucial step in the HCV lifecycle.
Pibrentasvir is targeted by the FDA-approved drug MAVYRET for treating HCV. There is currently no genetic evidence directly linking pibrentasvir to disease susceptibility.
MAVYRET, a small molecule drug developed by AbbVie, is the sole approved drug targeting pibrentasvir. It was first approved in 2017 for infectious disease indications.
Top pibrentasvir Drugs
AbbVie is the only company with an approved drug targeting pibrentasvir.
High market concentration indicates potential for new entrants with differentiated therapies.
pibrentasvir Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets pibrentasvir, using small molecule modality.
Exploring alternative modalities like antibodies could diversify therapeutic options.
pibrentasvir Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on pibrentasvir. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 | 100% |
| Phase 2 | 6 | 5 | 0 | 1 | 100% |
| Phase 3 | 13 | 13 | 0 | 0 | 100% |
| Phase 4 | 12 | 5 | 6 | 1 | 45% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
pibrentasvir Drug Approval Timeline (2017 - 2017)
MAVYRET was approved in 2017 and remains the only approved drug.
Limited approval history suggests potential for further innovation in HCV treatment.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 17 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on pibrentasvir. A trial counts if an approved drug acting on pibrentasvir is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.